The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

Annals of the Rheumatic Diseases

Volumn 72, Issue 11, 2013, Pages 1888-1890

  Plasencia, Ch ^a   Pascual Salcedo, D ^a   Alcocer, P ^a   Bonilla, M G ^a   Villalba, A ^a   Peiteado, D ^a   Arribas, F ^a   Diez J ^a   Lopez Casla, M T ^a   Martin Mola E ^a   Balsa, A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; INFLIXIMAB; METHOTREXATE;

ADULT; CLINICAL ARTICLE; CORRELATION ANALYSIS; DAS28; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ANTI-TNF; RHEUMATOID ARTHRITIS; TREATMENT;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; TIME FACTORS;

EID: 84885186042     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203353     Document Type: Letter

References (10)

1. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445-52.
2. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol 2012;24:306-11.
3. Finckh A, Dudler J, Wermelinger F, et al. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 2010;77:313-18.
4. Radstake T, Svenson M, Eijsbouts A, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
5. Wolbink GJ, Vis M, Lems WF, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15.
6. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-07.
7. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011;13:R105.
8. Hart MH, de VH, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196-203.
9. Aarden AL, Ruuls SR, Wolbink GJ. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008;20:431-35.
10. Wolbink GJ, Aarden AL, Dijkmans BA. Dealing with immunogenicity of biologicals: assesment and clinical relevance. Curr Opin Rheumatol 2009;21:211-15.